GlassScriptPhysician profile
Nancy L Witherspoon
NPI 1760481451
$17,196.63
in general payments reported to CMS, 2019-2025
42 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $757 · 2021: $723 · 2022: $996 · 2023: $1,115 · 2024: $1,280 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $3,073 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,590.00 |
| Food and Beverage | $3,073.13 |
| Education | $169.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $10,590.00 | 2025 | |
| Novo Nordisk INC | $1,308.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,002.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $407.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.22 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $357.50 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $274.64 | 2019-2023 | |
| Allergan, INC. | $272.45 | 2019-2020 | |
| Lilly USA, LLC | $256.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.67 | 2019-2024 | Xifaxan |
| Abbvie INC. | $234.56 | 2021-2024 | Vraylar, Linzess, Viberzi |
| Sumitomo Pharma America, INC. | $190.07 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $181.24 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $181.10 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $141.71 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Witherspoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.